Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064415 · ClinicalTrials.gov registry record · Phase 3
To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 799
- Enrollment target
NCT00064415 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 799 participants.
The verdict
NCT00064415, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 799 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD
Interventions
- DRUG Salmeterol
- DRUG arformoterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 799 participants |
| Start Date | 2002-06 |
| Est. Completion | 2004-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064415
The ClinicalTrials.gov registry entry for NCT00064415 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 799 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Salmeterol is the first listed.
NCT00064415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00064415 about?
NCT00064415 is a clinical study titled "To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD". The purpose of this study is to determine the long-term safety of arformoterol over a period of 12 months in subjects with COPD
What is the current status of trial NCT00064415?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 799 participants. The study started on 2002-06. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00064415?
The interventions under investigation include: Salmeterol (DRUG), arformoterol (DRUG).
Who is sponsoring clinical trial NCT00064415?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.